Skip to main content
Premium Trial:

Request an Annual Quote

SeraCare, Toma Bio Forge Codevelopment Partnership

NEW YORK (GenomeWeb) – SeraCare Life Sciences and Toma Biosciences announced today that they are entering into a codevelopment partnership.

Terms of the agreement call for SeraCare to provide Toma with access to its Seraseq Solid Tumor Mutation mix reference material technology to support the development and validation of Toma OS-Seq, a comprehensive solid tumor gene analysis kit, and Toma's upcoming PlasmaSeq liquid biopsy test.

Toma's OS-Seq proprietary technology aims to allow researchers to evaluate each gene in its panel for all mutation types, including copy number alterations, with a simplified single-day library prep method. 

"Seraseq reference materials with a comprehensive and customizable set of mutations are ideally suited to the comprehensive nature of the TOMA OS-Seq reagent kit," Federico Goodsaid, vice president of assay development and regulatory affairs at Toma Bioscience, said in a statement. 

"We are very excited to be working with Toma Biosciences and supporting their innovative OS-Seq technology with our Seraseq technology," Trevor Brown, vice president of precision medicine at SeraCare, said in a statement. "Our goal is to seek out mutually beneficial partnerships with NGS-based assay developers that leverage our ever-growing pipeline of innovative tools supporting better data quality in precision diagnostics."